natgillin/translations-raw huggingface dataset:
SOLUTION MUST NOT BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION. 
OPOZORILO: INTRAVENSKE RAZTOPINE ZDRAVILA CELLCEPT NE SMEMO DAJATI KOT HITRO INTRAVENSKO INJEKCIJO ALI V OBLIKI BOLUSA.
The pharmacokinetics of oral contraceptives were unaffected by co-administration of CellCept (see also section 4.5). 
Sočasno jemanje zdravila CellCept in peroralnih kontraceptivov ni vplivalo na farmakokinetiko peroralnih kontraceptivov (glejte tudi poglavje 4.5).
Renal and urinary disorders Blood creatinine increased 
Bolezni sečil zvišanje kreatinina v krvi zvišanje uree v krvi
Close bottle with child-resistant cap tightly. 
Steklenico tesno zaprite z za otroke varno zaporko.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses. 
• Dnevni odmerek je 4 tablete (2 g zdravila), razdeljenih na 2 posamezna odmerka.
The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. 
Kontracepcija pri moških, ki jemljejo zdravilo CellCept Razpoložljivi podatki ne kažejo na povečano tveganje za okvare ali splav, če mofetilmikofenolat uporablja oče.
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including CellCept. 
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom CellCept, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC
Uncommon Uncommon Uncommon 
agitacija anksioznost nenormalno mišljenje
CellCept tablets microcrystalline cellulose polyvidone (K-90) croscarmellose sodium magnesium stearate 
CellCept tablete mikrokristalna celuloza povidon (K90)
NAME OF THE MEDICINAL PRODUCT CellCept 1 g/5 ml powder for oral suspension. 
IME ZDRAVILA CellCept 1 g/5 ml prašek za peroralno suspenzijo
Each bottle contains 35 g mycophenolate mofetil in 110 g powder for oral suspension. 
• Vsaka steklenica vsebuje 35 g mofetilmikofenolata v 110 g praška za peroralno suspenzijo.
The recommended dose of CellCept for infusion in hepatic transplant patients is 1 g administered twice daily (2 g daily dose). 
Priporočeni odmerek infuzije zdravila CellCept pri bolnikih z jetrnim presadkom je 1 g dvakrat na dan (dnevni odmerek 2 g).
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION CellCept 1 g/5 ml powder for oral suspension mycophenolate mofetil 
IME ZDRAVILA IN POT(I) UPORABE CellCept 1 g/5 ml prašek za peroralno suspenzijo mofetilmikofenolat
• The daily dose is 12 capsules (3 g of the medicine) taken as 2 separate doses. 
• Dnevni odmerek je 12 kapsul (3 g zdravila), razdeljenih na 2 posamezna odmerka.
Always take CellCept exactly as your doctor has told you. 
Pri jemanju zdravila CellCept natančno upoštevajte navodila zdravnika.
Vascular disorders Hypertension 
Žilne bolezni hipertenzija hipotenzija limfokela venska tromboza vazodilatacija
Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans. 
• ozadje teratogenosti in mutagenosti mofetilmikofenolata pri ljudeh
• Capsule shell: gelatin, indigo carmine (E132), yellow iron oxide (E172), red iron oxide (E172), 
• ovojnica kapsule: želatina, indigotin (E132), rumeni železov oksid (E172), rdeči železov oksid (E172), titanov dioksid (E171), črni železov oksid (E172), kalijev hidroksid, šelak.
IV CellCept should continue for the first 4 days following hepatic transplant, with oral CellCept initiated as soon after this as it can be tolerated. 
Prve 4 dni po presaditvi jeter je treba dajati zdravilo CellCept intravensko, takoj ko je bolnik sposoben požirati, pa nadaljujemo s peroralno obliko zdravila CellCept.
Immune system disorders Hypersenstivity 
Bolezni imunskega sistema preobčutljivost hipogamaglobulinemija zelo redki
The usable volume of the reconstituted suspension is 160-165 ml. 
Uporabni volumen pripravljene suspenzije je 160-165 ml Priložena sta 1 nastavek za steklenico in 2 peroralna razdelilnika
The full name of your medicine is CellCept 250 mg capsules. 
Kaj je zdravilo CellCept in za kaj ga uporabljamo Celotno ime zdravila je CellCept 250 mg kapsule.
There is no information for the use of CellCept in children with a heart transplant. 
• Podatki o uporabi zdravila CellCept pri otrocih s srčnim presadkom niso na voljo.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g CellCept twice daily. 
Vrsta in pogostnost neželenih učinkov v kliničnih študijah, ki so zajele 92 otrok in mladostnikov, starih od 2 do 18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g zdravila CellCept dvakrat na dan. Naslednji neželeni učinki, povezani z zdravljenjem, pa so bili v primerjavi z odraslimi pogostejši pri otrocih in mladostnikih, zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
The health professional educational material should contain: · The Summary of Product Characteristics · Guide for healthcare professionals 
Izobraževalno gradivo za zdravstvene delavce mora vsebovati:
Very Common Very Common Common 
KAKOVOSTNA IN KOLIČINSKA SESTAVA
CellCept 500 mg powder for concentrate for solution for infusion 
Navodilo za uporabo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje
No pharmacokinetic data with CellCept for infusion are available for paediatric renal transplant patients. 
Za otroke in mladostnike z ledvičnim presadkom podatkov o farmakokinetiki infuzije zdravila CellCept ni na voljo.
Keep in outer carton in order to protect from light. 
• Shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
• Do not use the capsules after the expiry date stated on the carton (EXP). 
• Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli
The final concentration of the solution is 6 mg/mL mycophenolate mofetil. 
Končna koncentracija mofetilmikofenolata v raztopini je 6 mg/ml.
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg tablets mycophenolate mofetil 
IME ZDRAVILA CellCept 500 mg tablete mofetilmikofenolat
Severe hepatic impairment No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. 
Bolnikom z ledvičnim presadkom in hudo boleznijo jetrnega parenhima ni treba prilagajati odmerkov.
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg film-coated tablets Mycophenolate mofetil 
IME ZDRAVILA CellCept 500 mg filmsko obložene tablete mofetilmikofenolat
The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses. 
• Dnevni odmerek je 6 tablet (3 g zdravila), razdeljenih na 2 posamezna odmerka.
The recommended dose of oral CellCept in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose). 
Priporočeni peroralni odmerek zdravila CellCept pri bolnikih z jetrnim presadkom je 1,5 g dvakrat na dan (dnevni odmerek 3 g).
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/002 CellCept 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/96/005/002 CellCept
STATEMENT OF ACTIVE SUBSTANCE(S) 5 ml suspension contains 1 g mycophenolate mofetil when reconstituted. 
NAVEDBA ENE ALI VEČ UČINKOVIN 5 ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
Inspect the resulting solution for particulate matter and discoloration prior to further dilution. 
Pred razredčitvijo preverite, da dobljena raztopina ne vsebuje vidnih delcev in da ni razbarvana.
Diarrhoea, leucopenia, sepsis and vomiting were among the most common and/or serious adverse drugs reactions associated with the administration of CellCept in combination with ciclosporin and corticosteroids. 
Med najpogostejšimi in/ali najbolj resnimi neželenimi učinki, povezanimi z uporabo zdravila CellCept v kombinaciji s ciklosporinom in kortikosteroidi, so bili driska, levkopenija, sepsa in bruhanje.
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/001 CellCept 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/96/005/001 CellCept
Hepatobiliary disorders Blood alkaline phosphatase increased 
Bolezni sečil zvišanje kreatinina v krvi zvišanje uree v krvi hematurija okvara ledvic
The full name of your medicine is CellCept 1 g/5 ml powder for oral suspension. 
Kaj je zdravilo CellCept in za kaj ga uporabljamo Celotno ime zdravila je CellCept 1 g/5 ml prašek za peroralno suspenzijo.
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg powder for concentrate for solution for infusion. 
IME ZDRAVILA CellCept 500 mg prašek za koncentrat za raztopino za infundiranje
Contents of the pack and other information What CellCept film coated tablet contains 
Kaj vsebuje zdravilo CellCept filmsko obložene tablete
There is no basis for CellCept dose adjustment following cardiac transplant rejection. 
Pri zavrnitvi srčnega presadka prilagajanje odmerkov zdravila CellCept ni potrebno.
No data are available for hepatic transplant patients with severe chronic renal impairment. 
Za bolnike z jetrnim presadkom in hudo ledvično okvaro podatkov ni.
The mean single dose MPAG AUC was 3 - 6 fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. 
Pri bolnikih s hudo ledvično okvaro je bil srednji AUC mikofenolglukuronida po enkratnem odmerku od 3- do 6krat večji kot pri bolnikih z blažjimi stopnjami ledvične okvare ali pri zdravih prostovoljcih.
No data are available for cardiac transplant patients with severe hepatic parenchymal disease. 
Za bolnike s srčnim presadkom in hudo boleznijo jetrnega parenhima podatkov ni.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start CellCept: 
Nemudoma se pogovorite z zdravnikom, preden se začnete zdraviti z zdravilom CellCept,:
Discard the vial if particulate matter or discoloration is observed. 
Če opazite vidne delce ali razbarvanje, vialo zavrzite.
OTHER SPECIAL WARNING(S), IF NECESSARY CellCept capsules should be handled with care Do not open or crush the capsules and breathe the powder inside the capsules or allow it to touch your skin 
CellCept kapsule je treba uporabljati previdno Kapsul ne odpirajte in ne drobite
The full name of your medicine is CellCept 500 mg film-coated tablets. 
Kaj je zdravilo CellCept in za kaj ga uporabljamo Celotno ime zdravila je CellCept 500 mg filmsko obložene tablete.
This leaflet was last revised on {MM/YYYY} 
Priporočljivo je, da je drugi test opravljen
If you think that you have had too much medicine, talk to your doctor or nurse straight away. 
Če ste prejeli večji odmerek zdravila CellCept, kot bi smeli Če mislite, da ste prejeli preveč zdravila, takoj obvestite zdravnika ali medicinsko sestro.
Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan) Concomitant administration of drugs affecting glucuronidation of MPA may change MPA exposure. 
Sočasna uporaba zdravil, ki vplivajo na glukuronidacijo mikofenolne kisline, lahko spremeni izpostavljenost mikofenolni kislini.
CellCept 500 mg powder for concentrate for solution for infusion polysorbate 80 citric acid hydrochloric acid sodium chloride 
CellCept 500 mg prašek za koncentrat za raztopino za infundiranje polisorbat 80
There is no information for the use of CellCept in children with a liver transplant. 
Otroci • Podatki o uporabi zdravila CellCept pri otrocih s srčnim presadkom niso na voljo.
The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients. 
Hrana na obseg absorpcije mofetilmikofenolata (AUC mikofenolne kisline), če ga dajemo v odmerkih 1,5 g dvakrat na dan bolnikom s presajeno ledvico, ne vpliva, zmanjša pa največjo plazemsko koncentracijo (Cmax) mikofenolne kisline za približno 40 %.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 500 mg mycophenolate mofetil. 
Ena tableta vsebuje 500 mg mofetilmikofenolata.
Lung problems such as: pneumonia, bronchitis, shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). 
Bolezni dihal, prsnega koša in mediastinalnega prostora bronhiektazija kašelj dispneja intersticijska bolezen pljuč zelo redki plevralni izliv pljučna fibroza zelo redki
Contraception in women taking CellCept 
Vgraviran imajo napis “CellCept
HOW TO STORE CELLCEPT 
Shranjevanje zdravila CellCept
Skin and subcutaneous tissues disorders Acne 
Bolezni kože in podkožja akne alopecija izpuščaj hipertrofija kože
The recommended dose of 1 g administered twice a day for renal or hepatic transplant patients is appropriate for the elderly. 
Starejši bolniki Priporočeni odmerek za starejše bolnike je 1 g dvakrat na dan za bolnike z ledvičnim ali jetrnim presadkom.
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/006 
ŠTEVILKA€ DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/006
If you are not sure, talk to your doctor or pharmacist before taking CellCept. 
Če ste negotovi glede jemanja zdravila CellCept, se pred tem pogovorite z zdravnikom ali farmacevtom.
There have been reports of aplastic anaemia and bone marrow failure in patients treated with CellCept, some of which have been fatal Cases of pure red cell aplasia (PRCA) have been reported in patients treated with CellCept (see section 4.4). 
Pri zdravljenju z zdravilom CellCept v kombinaciji z drugimi imunosupresivi so poročali o primerih čiste aplazije rdečih krvnih celic (PRCA - pure red cell aplasia).
• Microphthalmia; 
• ledvične nenormalnosti.
Kidney transplant Adults 
Uporaba pri presaditvi ledvic Odrasli
Congenital malformations, including reports of multiple malformations, have been observed postmarketing in children of patients exposed to CellCept during pregnancy in combination with other immunosuppressants. 
Pri otrocih bolnic, ki so se v času nosečnosti zdravile z zdravilom CellCept v kombinaciji z drugimi imunosupresivi, so po prihodu zdravila na trg poročali o kongenitalnih malformacijah, vključno z večkratnimi malformacijami.
• tablet coating: hydroxypropyl methycellulose, hydroxypropyl cellulose, titanium dioxide 
hiperholesterolemija hiperglikemija hiperkaliemija hiperlipidemija hipokalciemija hipokaliemija hipomagneziemija hipofosfatemija hiperurikemija protin zmanjšanje telesne mase
CellCept should be administered with caution in patients with active serious digestive system disease. 
Bolnikom s hujšimi boleznimi prebavil v aktivnih fazah dajemo zdravilo CellCept zelo previdno in pod skrbnim zdravniškim nadzorom.
Blood urea increased 
• kri v urinu
If you are not sure, talk to your doctor or nurse before having CellCept. 
Če ste negotovi glede jemanja zdravila CellCept, se pred tem pogovorite z zdravnikom ali medicinsko sestro.
Digestive system and mouth problems such as: swelling of the gums and mouth ulcers, inflammation of the pancreas, colon or stomach, gastrointestinal disorders including bleeding, liver problems, 
Bolezni jeter, žolčnika in žolčevodov zvišanje alkalne fosfataze v krvi zvišanje laktat-dehidrogenaze v krvi zvišanje jetrnih encimov hepatitis hiperbilirubinemija zlatenica
The full name of your medicine is CellCept 500 mg powder for concentrate for solution for infusion. 
Kaj je zdravilo CellCept in za kaj ga uporabljamo Celotno ime zdravila je CellCept 500 mg prašek za koncentrat za raztopino za infundiranje.
Bone marrow failure 
Huda jetrna okvara
Renal transplant The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose). 
Ledvični presadek Priporočeni odmerek pri bolnikih z ledvičnim presadkom je 1 g dvakrat na dan (dnevni odmerek 2 g).
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/002 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/002
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg film-coated tablets. 
Navodilo za uporabo CellCept 500 mg filmsko obložene tablete
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/004 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/004
Do not open or crush the capsules and breathe the powder inside the capsules or allow it to touch your skin 
Izogibajte se vdihavanju ali neposrednemu stiku praška s kožo
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/005 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/005
Nervous system problems such as: feeling drowsy or numb, tremor, muscle spasms convulsions, feeling anxious or depressed changes in your mood or thoughts. 
• občutek strahu ali depresije, spremembe v razpoloženju ali načinu mišljenja.
Venous thrombosis 
hematurija okvara ledvic
PHARMACEUTICAL FORM AND CONTENTS 50 Tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 4 viale
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/001
A kidney or liver. 
• Presadek je lahko ledvični ali jetrni.
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/003 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/96/005/003
• reduce discomfort. 
• zmanjšanje nelagodja.
• reduce the risk of new infections of the udder during the dry period, 
• zmanjšanje tveganja novih okužb vimen med obdobjem presušitve,
A third field study involved 228 dairy cows. 
Tretja terenska študija je vključevala 228 krav molznic.
The European Commission granted a marketing authorisation valid throughout the EU for Velactis on 9 December 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Velactis, veljavno po vsej Evropski uniji, izdala 9. decembra 2015.
The full EPAR for Velactis can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila za zdravilo Velactis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Velactis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Velactis.
Cabergoline has a long-lasting action on receptors in these cells (called D2 receptors) that block release of the hormone. 
Kabergolin ima dolgotrajen učinek na receptorje na teh celicah (imenovane receptorji D2), ki zavirajo sproščanje hormona.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Velactis' benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Velactis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
It is not intended to provide practical advice on how to use Velactis. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
• reduce milk leakage at drying off (the point at which the cow is no longer milked), 
• zmanjšanje uhajanja mleka ob presuševanju (čas, ko krave ne molzemo več),
Velactis is used to: 
Zdravilo Velactis se uporablja za:
Hands should be washed after handling the product. 
Po ravnanju z zdravilom si je treba umiti roke.
By blocking prolactin release in this way, milk production is reduced. 
S takšnim zaviranjem sproščanja prolaktina se zmanjša proizvodnja mleka.
Velactis is a medicine used in the herd management programme of dairy cows as an aid to reduce milk production in dairy cows at the start of the dry period (the period when the cow is not milked before calving and start of the next lactation). 
Velactis je zdravilo, ki se uporablja v programu upravljanja čred krav molznic kot pomoč pri zmanjševanju proizvodnje mleka pri kravah molznicah na začetku obdobja presušitve (obdobja, ko krave pred telitvijo in začetkom naslednje laktacije ne molzemo).
It contains the active substance cabergoline. 
Vsebuje zdravilno učinkovino kabergolin.
The most common side effects with Velactis (which may affect up to 1 in 10 cows) are slight injection site reactions (mostly swellings) after injection of the product which may persist for at least 7 days. 
Najpogostejši neželeni učinki zdravila Velactis (ki lahko prizadenejo največ 1 od 10 krav) so blage reakcije na mestu injiciranja (v glavnem otekanje) po injiciranju zdravila, ki lahko trajajo vsaj 7 dni.
Velactis reduced the incidence of milk leakage to 2% compared to 10.7% in the cows treated with placebo. 
Zdravilo Velactis je zmanjšalo pojavnost uhajanja mleka na 2 %, v primerjavi z 10,7 % pri kravah, zdravljenih s placebom.
People who are hypersensitive (allergic) to cabergoline should avoid contact with Velactis. 
Ljudje, ki so preobčutljivi za (alergične na) kabergolin, se morajo izogibati stiku z zdravilom Velactis.
What is Velactis and what is it used for? 
Kaj je zdravilo Velactis in za kaj se uporablja?
Pregnant women and women attempting to conceive should avoid contact with Velactis. 
Nosečnice in ženske, ki se trudijo zanositi, naj se izogibajo stiku z zdravilom Velactis.
What benefits of Velactis have been shown in studies? 
Kakšne koristi je zdravilo Velactis izkazalo v študijah?
The withdrawal period for meat from dairy cows treated with Velactis is 23 days. 
Karenca za meso krav molznic, zdravljenih z zdravilom Velactis, je 23 dni.
As Velactis reduces milk production, breastfeeding women should also avoid contact with the product. 
Ker zdravilo Velactis zmanjšuje proizvodnjo mleka, naj se stiku z zdravilom izogibajo tudi ženske, ki dojijo.
Milk production is stimulated by a hormone, prolactin, released from specialised cells in the pituitary gland (a small gland attached to the brain). 
Proizvodnjo mleka spodbuja hormon prolaktin, ki se sprošča iz posebnih celic v hipofizi (majhni žlezi, ki se drži možganov).
Why is Velactis approved? 
Zakaj je bilo zdravilo Velactis odobreno?
What are the risks associated with Velactis? 
Kakšna tveganja so povezana z zdravilom Velactis?
In a second field study involving 263 dairy cows the percentage of Velactis-treated cows with milk leakages during a 14-day period after drying-off was 3.9% compared with 17.6% for the cows treated with placebo. 
V drugi terenski študiji, v katero je bilo vključenih 263 krav molznic, je mleko v 14-dnevnem obdobju po presušitvi uhajalo pri 3,9 % krav, zdravljenih z zdravilom Velactis, in pri 17,6 % krav, zdravljenih s placebom.
The withdrawal period for milk from dairy cows treated with Velactis is ‘zero' days, which means there is no mandatory waiting time after calving, if the dry period length is 32 days or more. 
Karenca za mleko krav molznic, zdravljenih z zdravilom Velactis, je nič dni, kar pomeni, da po telitvi ni obvezne čakalne dobe, če obdobje presušitve traja vsaj 32 dni.
Velactis treated cows showed reduced discomfort on the first day of drying-off as indicated by increased daily lying time. 
Pri kravah, zdravljenih z zdravilom Velactis, je prišlo do zmanjšanja nelagodja prvi dan presušitve, kar se je pokazalo kot podaljšan čas dnevnega ležanja.
Other information about Velactis? 
Druge informacije o zdravilu Velactis
Velactis is given as a single injection into the muscle within four hours of the last milking on the day of drying off. Velactis is available as a solution for injection in multidose vials of 5 ml, 25 ml or 50 ml. 
Zdravilo Velactis je na voljo kot raztopina za injiciranje v večodmernih vialah s 5 ml, 25 ml ali 50 ml.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor. 
V primeru nenamernega samo-injiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.